



Attorney Docket No. 5957.200-US 0776/1H462-US1

Andersen et al.

Serial No. 09/659,622 Filed September 11, 2000

Attorney Docket No.: 5957.200-US 0776/1H462-US1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Confirmation No.: 5060

Application No.: 09/659,622

Group Art Unit: 1614

Filed: September 11, 2000

Examiner: Krass, Frederick F.

For: Method of Inhibiting Protein Tyrosine Phosphatase 1B and/or T-cell Protein Tyrosine Phosphatase and/or Other PTPases with an Asp Residue at Position 48

AMENDMENT/RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This amendment is timely submitted in response to the final Office Action on the merits mailed October 20, 2004, having a shortened statutory period for reply set to expire January 20, 2005, subject to extensions of time under the provisions of 37 CFR §1.136(a).

Applicant believes no fee is necessary to timely file this paper. However, should any petition or fee be required for timely filing of this Amendment, Applicant hereby petitions for such Extension of Time and hereby grants authorization to charge Deposit Account No. 14-1447, in the name of Novo Nordisk, Inc., for any such required fee.

The examiner states in the Office Action Summary that claims numbered 1-25 and 28-36 are pending in the application; claims numbered 14, 15, 19, 24 and 25 are withdrawn from consideration; claims numbered 28 and 32-36 are allowed; and claims numbered 1-13, 16-18, 20-23 and 29-31 are rejected.

Pursuant to 37 C.F.R. §1.121, Applicant submits a complete listing of all of the claims ever presented for this pending application.

Claims numbered 1-25 and 29-31 are cancelled herein.

Applicant submits herewith an initial computer readable form (CRF) copy of the sequence listing and an initial paper copy. Applicant states the content of the sequence listing information recorded in the CRF is identical to the written sequence listing and includes no new matter.

oh
to enter
al
3/10/05